I'm thrilled to sit down with Dr. Ivan Kairatov, a renowned expert in pediatric medicine with a focus on liver transplantation and patient-reported outcomes. With years of experience in research and innovation, Dr. Kairatov has been at the forefront of shifting how we understand children's
What happens when a beacon of hope for millions battling multiple sclerosis (MS) dims in a single clinical trial? In a field where breakthroughs are rare and desperately needed, Contineum Therapeutics, a San Diego-based biotech firm, has hit a significant roadblock with their lead drug, PIPE-307,
In the high-stakes world of intensive care units (ICUs), severe community-acquired pneumonia (CAP) stands as a formidable adversary, often demanding prolonged hospital stays and extensive resources like ventilatory support, especially among older adults. This condition, contracted outside hospital
The alarming statistic that individuals with type 1 diabetes face a 4.29-fold increased risk of developing bladder cancer has sent ripples through the medical community, challenging long-held assumptions about the intersection of metabolic disorders and malignancies. With bladder cancer already
In a landscape where lung cancer remains one of the most challenging diseases to treat, particularly for rare subsets of patients, a new development has sparked hope among clinicians and affected individuals alike. Bayer’s recently approved drug, sevabertinib, marketed as Hyrnuo, has gained
In a groundbreaking development for rheumatoid arthritis treatment, Lifordi Immunotherapeutics, a clinical-stage biotech firm headquartered in Burlington, Massachusetts, has successfully raised $112 million in a funding round led by Sanofi Ventures, with continued support from prominent investors
